1 active not recruiting, 1 unknown. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Resistant Cancer: new trials by email Literature Review of Resistant Cancer trials Research Report on Resistant Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lorlatinib Combinations in Lung Cancer Lorlatinib, Crizotinib, Binimetinib - Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation | Phase 1 / Phase 2 | Unknown | Massachusetts General Hospital | 96 | 2020-05-01 | 2021-03-10 |
| 9-ING-41 in Patients With Advanced Cancers 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin. - Cancer, Pancreatic Cancer | Phase 2 | Active not recruiting | Actuate Therapeutics Inc. | 350 | 2019-01-04 | 2026-04-03 |
Lung Neoplasms (2) · Bone Neoplasms (1) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Glioma (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Kidney Neoplasms (1) · Leukemia-Lymphoma, Adult T-Cell (1) · Lymphoma, Non-Hodgkin (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Recurrence (1) · Sarcoma (1)
Lung Diseases (2) · Neoplasms by Site (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Bone Diseases (1) · Breast Diseases (1) · Colonic Diseases (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1)
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (1) · Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Crizotinib (1) · Doxorubicin (1) · Gemcitabine (1) · Irinotecan (1) · Lomustine (1) · Paclitaxel (1) · Taxes (1) · binimetinib (1) · liposomal doxorubicin (1) · lorlatinib (1)
Actuate Therapeutics Inc. (1) · Massachusetts General Hospital (1)
United States (2) · Belgium (1) · Canada (1) · France (1) · Netherlands (1) · Portugal (1) · Spain (1)
PMID 24327518, PMID 27424289, PMID 28053024, PMID 28672195, PMID 29383130, PMID 29846250, PMID 30405781, PMID 30975030, PMID 31101621, PMID 31401903, PMID 31533931, PMID 31831767, PMID 31882719, PMID 31894292, PMID 35815408, PMID 41981308